Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Chubb
Farmers Insurance
Daiichi Sankyo
Mallinckrodt
Covington
US Army
QuintilesIMS
Chinese Patent Office

Generated: February 19, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SELENOMETHIONINE SE 75

« Back to Dashboard

Clinical Trials for Selenomethionine Se 75

Trial ID Title Status Sponsor Phase Summary
NCT00112892 Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors Completed Roswell Park Cancer Institute Phase 1 RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenium may allow higher doses of irinotecan to be given. Giving irinotecan together with selenium may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of selenium when given together with irinotecan in treating patients with advanced solid tumors.
NCT00212186 Selenium Supplementation of Patients With Cirrhosis Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) N/A The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
NCT00212186 Selenium Supplementation of Patients With Cirrhosis Completed Vanderbilt University Medical Center N/A The purpose of this study is to determine whether patients with liver disease can improve their nutritional selenium status by taking supplemental selenium.
NCT00217516 Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer Completed National Cancer Institute (NCI) Phase 1 RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving selenium before brachytherapy may be an effective treatment for prostate cancer. PURPOSE: This randomized phase I trial is studying selenium to see how well it works compared to placebo in treating patients who are undergoing brachytherapy for stage I or stage II prostate cancer.
NCT00217516 Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer Completed Roswell Park Cancer Institute Phase 1 RATIONALE: The use of nutritional supplements, such as selenium, may stop prostate cancer from growing. Internal radiation, such as brachytherapy, uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving selenium before brachytherapy may be an effective treatment for prostate cancer. PURPOSE: This randomized phase I trial is studying selenium to see how well it works compared to placebo in treating patients who are undergoing brachytherapy for stage I or stage II prostate cancer.
NCT00526890 Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Terminated Roswell Park Cancer Institute Phase 2 RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenomethionine may slow the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together with selenomethionine and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying the side effects and how well selenomethionine works when given together with carboplatin, paclitaxel, and radiation therapy in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery.
NCT00625183 Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma Terminated National Cancer Institute (NCI) Phase 2 RATIONALE: Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Selenomethionine may slow the growth of tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving combination chemotherapy together With selenomethionine and radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well selenomethionine works when given together with capecitabine, oxaliplatin, and radiation therapy in treating patients undergoing surgery for newly diagnosed stage II or stage III rectal cancer.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Selenomethionine Se 75

Condition Name

Condition Name for Selenomethionine Se 75
Intervention Trials
Prostate Cancer 2
No Evidence of Disease 1
Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity 1
Advanced Metastatic Clear Cell Renal Cell Carcinoma (CCRCC) 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Selenomethionine Se 75
Intervention Trials
Prostatic Neoplasms 3
Carcinoma 2
Carcinoma, Renal Cell 1
Carcinoma, Non-Small-Cell Lung 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Selenomethionine Se 75

Trials by Country

Trials by Country for Selenomethionine Se 75
Location Trials
United States 11
New Zealand 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Selenomethionine Se 75
Location Trials
New York 7
Tennessee 2
Iowa 1
Illinois 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Selenomethionine Se 75

Clinical Trial Phase

Clinical Trial Phase for Selenomethionine Se 75
Clinical Trial Phase Trials
Phase 2 4
Phase 1 4
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Selenomethionine Se 75
Clinical Trial Phase Trials
Completed 5
Terminated 3
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Selenomethionine Se 75

Sponsor Name

Sponsor Name for Selenomethionine Se 75
Sponsor Trials
Roswell Park Cancer Institute 6
National Cancer Institute (NCI) 4
Vanderbilt University Medical Center 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Selenomethionine Se 75
Sponsor Trials
Other 8
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Queensland Health
Express Scripts
Dow
Cantor Fitzgerald
Citi
Chubb
Harvard Business School
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.